The ocular melanoma story - LIII Edward Jackson Memorial Lecture .2.
The ocular melanoma story - LIII Edward Jackson Memorial Lecture .2.
复制标题
DOI：
10.1016/s0002-9394(14)71119-5
复制
发表时间：
1997-06-01
影响因子：
4.2
通讯作者：
Albert, DM
中科院分区：
文献类型：
--
作者：
Albert, DM
目得：追溯脉络膜黑色素瘤的性质、病因和治疗方面的知识的演变和现状。方法：回顾历史资料，从Georg Bartisch在1583年的贡献到眼黑色素瘤协作研究和最近的基础研究。结果：许多人对我们了解这种肿瘤做出了重要贡献，然而，关于肿瘤的自然史，最有效的治疗方法，其原因是缺乏。结论：眼黑色素瘤协作研究将提供关于在眼球摘除和放射治疗之间选择治疗的重要信息，以及自然病史信息、生活质量和明确的病理学发现，脉络膜黑色素瘤的持续治疗将取决于对导致肿瘤的遗传缺陷的了解，在未来25年内，据预测，遗传缺陷将被确定，肿瘤样品将使用小针抽吸和位于微芯片上的DNA探针获得。此外，治疗将基于设计用于抑制与肿瘤中遗传缺陷相关的分子的药物。
PURPOSE: To trace the evolution and status of our knowledge of choroidal melanoma with regard to the nature, cause, and treatment of this tumor.METHODS: Historical materials beginning with Georg Bartisch's contributions in 1583 through to the Collaborative Ocular Melanoma Study and recent basic research are reviewed.RESULTS: Many individuals have made important contributions to our knowledge about this tumor, Basic information, however, regarding the natural history of the tumor, the most effective treatment, and its cause is lacking.CONCLUSION: The Collaborative Ocular Melanoma Study will provide important information regarding the choice of treatment between enucleation and radiotherapy as well as natural history information, quality of life, and definitive pathology findings, Definitive treatment of choroidal melanoma will depend on knowledge of the genetic defects that cause the tumor, Within the next 25 years, it is predicted that genetic defects will be determined and tumor samples will be obtained using small needle aspiration and DNA probes located on microchips, In addition, treatment will then be based on drugs designed to inhibit molecules related to the genetic defect in the tumor.